US · PRTC
PureTech Health plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02210
- Website
- puretechhealth.com
Price · as of 2024-12-31
$18.14
Market cap 405.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.55 | +95.98% |
| Intrinsic Value(DCF) | $9,601.52 | +52,830.1% |
| Graham-Dodd Method(GD) | $25.30 | +39.48% |
| Graham Formula(GF) | $101.55 | +459.8% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $2.37 | |||
| 2014 | $0.00 | $306.84 | |||
| 2015 | $1.57 | $0.00 | |||
| 2016 | $0.00 | $109.20 | |||
| 2017 | $15.26 | $0.00 | |||
| 2018 | $2.09 | $0.00 | |||
| 2019 | $94.78 | $0.00 | |||
| 2020 | $58.00 | $43.98 | $54.28 | $23.38 | $0.86 |
| 2021 | $26.79 | $107.52 | $23.83 | $10.14 | $0.00 |
| 2022 | $27.00 | $30.04 | $11.63 | $10.38 | $121.38 |
| 2023 | $25.57 | $35.32 | $12.64 | $4.91 | $0.00 |
| 2024 | $17.95 | $35.55 | $11.64 | $25.30 | $101.55 |
AI valuation
Our deep-learning model estimates PureTech Health plc's (PRTC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.55
- Current price
- $18.14
- AI upside
- +95.98%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9,601.52
+52,830.1% upside
Graham-Dodd
$25.30
+39.48% upside
Graham Formula
$101.55
+459.8% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRTC | PureTech Health plc | $18.14 | 405.3M | +96% | +52,830% | +39% | +460% | 17.42 | 1.17 | 100.26 | 3.72 | — | 1.17 | 26.04% | -2818.87% | 1108.33% | 6.32% | -117.31% | 4.29% | 0.05 | -13.56 | 9.33 | 9.19 | -6.91 | -18333.00% | 4498.00% | 2658.00% | -27.76% | -3.25 | -115.83% | 0.00% | 0.00% | 41.34% | -1.02 | -1.04 | 28.81 | 1.52 |
| ADCT | ADC Therapeutics S.A. | $4.10 | 507.9M | +465% | -82% | — | — | -1.13 | -0.88 | 2.52 | -0.50 | — | -0.88 | 91.60% | -184.44% | -222.83% | 89.97% | 41.28% | -46.65% | -0.61 | -2.60 | 3.82 | 3.37 | 1.25 | -4490.00% | 184.00% | 230.00% | -69.75% | -1.54 | 39.40% | 0.00% | 0.00% | 0.00% | -0.39 | -0.41 | 0.72 | -6.56 |
| ALMS | Alumis Inc. Common Stock | $29.69 | 3.1B | — | — | — | — | -0.47 | 0.53 | — | 0.40 | -0.19 | 0.53 | 0.00% | — | — | 743.42% | 170.37% | -136.66% | 0.12 | — | 6.01 | 5.70 | 0.47 | 24716.00% | — | 9097.00% | -185.69% | -5.01 | 145.47% | 0.00% | 0.00% | 90.66% | 0.40 | 0.46 | — | -3.69 |
| AUTL | Autolus Therapeutics plc | $1.71 | 455.11M | +3,826% | -33% | — | — | -2.32 | 1.20 | 50.68 | 0.10 | — | 1.24 | -1293.48% | -2385.63% | -2180.45% | -81.91% | 263.57% | -38.11% | 0.12 | -25.98 | 10.88 | 10.47 | 0.75 | -2750.00% | 49600.00% | 5398.00% | -47.01% | -3.40 | 263.21% | 0.00% | 0.00% | 0.00% | 0.09 | 0.09 | -2.23 | -1.19 |
| BNTC | Benitec Biopharma Inc. | $10.90 | 286.09M | — | — | — | — | -13.28 | 5.18 | — | -9.76 | — | 5.18 | 0.00% | — | — | -52.46% | 2846.97% | -49.96% | 0.01 | — | 54.67 | 54.26 | 2.32 | -6082.00% | — | 2055.00% | -4.69% | -13.09 | 1609.13% | 0.00% | 0.00% | 9.20% | -9.74 | -17.23 | — | 128.14 |
| NGNE | Neurogene Inc. | $23.49 | 363.86M | — | -49% | — | — | -4.04 | 0.98 | 328.17 | -0.05 | -7.88 | 0.98 | -251.03% | -8930.27% | -8123.68% | -30.28% | -1064.50% | -26.92% | 0.04 | -6883.75 | 20.84 | 20.65 | 1.73 | 5124.00% | — | 3801.00% | -23.52% | -4.66 | -920.24% | 0.00% | 0.00% | 0.00% | -0.04 | -0.05 | 3.87 | 6.36 |
| NMRA | Neumora Therapeutics, Inc… | $3.49 | 583.14M | — | — | — | — | -0.97 | 0.83 | — | 0.26 | -36.29 | 0.83 | 0.00% | — | — | -64.48% | -31666.35% | -59.96% | 0.01 | — | 10.51 | 10.29 | 0.53 | 268.00% | — | 1196.00% | -77.03% | -6.12 | -21987.50% | 0.00% | 0.00% | 0.00% | 0.26 | 0.37 | — | -1.09 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| RCKT | Rocket Pharmaceuticals, I… | $5.01 | 542.19M | — | — | — | — | -2.48 | 1.99 | — | -2.38 | — | 2.59 | 0.00% | — | — | -60.27% | -135.95% | -52.00% | 0.09 | -122.55 | 6.38 | 2.57 | 0.25 | -2637.00% | — | -1166.00% | -34.48% | -6.29 | -111.72% | 0.00% | 0.00% | 0.00% | -2.16 | -2.62 | — | -1.60 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
About PureTech Health plc
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- CEO
- Robert Lyne
- Employees
- 80
- Beta
- 0.72
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9,601.52 ÷ $18.14) − 1 = +52,830.1% (DCF, example).